Covidien Makes Deal With Watson To Allow Generic Exalgo

Law360, New York (January 25, 2012, 7:57 PM EST) -- Zalicus Inc. on Wednesday said Covidien PLC, with which it partners on Covidien's painkiller Exalgo, has agreed to a settlement with Watson Pharmaceuticals Inc. that will allow a generic version of Exalgo to hit the market before the expiration of Covidien's patent.

Under the terms of the settlement between Covidien subsidiary Mallinckrodt Inc. and Watson Pharmaceuticals Inc.-Florida, Watson can introduce a generic version of hydromorphone hydrochloride extended-release tablets on Nov. 15, 2013, several months before the July 7, 2014 expiration of the patent covering the tablets,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.